Illumina announces expansion of TruSight Oncology portfolio

Illumina, Inc. has announced the release of TruSight™ Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable comprehensive genomic profiling (CGP). The assay is currently under development, with global release planned for mid-2025. Detailed plans for the product were shared in a spotlight presentation at the 2024 meeting of the Association of Molecular Pathology (AMP) in Vancouver, Canada.

TSO 500 v2 assesses hundreds of genes across all variant classes, and immuno-oncology biomarkers, in a single assay from one sample, to facilitate therapy selection research.

Key features of TSO 500 v2 include:

• Faster turnaround time and reduced hands-on time
• Sensitive variant calling and improved coverage of difficult genomic regions
• Gold-standard Myriad^® Genomic Instability Score (GIS) to determine homologous recombination deficiency (HRD) status, included for all samples
• New kit configurations with 50% less packaging, 70% fewer tubes, and improved usability
• Automation methods available with flexible batch sizes
• Integrated and automated data analysis, from sequencer to insights supported with DRAGEN^™ secondary analysis and Illumina Connected Insights, or Velsera's Clinical Genomics Workspace (CGW)
• Broad platform compatibility

At AMP, several abstracts accepted for poster presentations demonstrated preliminary analytical performance data and automation compatibility of TSO 500 v2. The studies support the assay's applications for clinical research in identifying rare genetic biomarkers and fusion biomarkers.

CGP is a critical tool for identifying actionable alterations, including rare mutations, which enables precision medicine in accordance with professional guidelines. At AMP, several customer-led poster presentations provided further evidence for the clinical utility of CGP and demonstrated its versatility in hospital and community oncology care settings.

Illumina also cohosted a workshop with Bayer, featuring a panel discussion of key opinion leaders on the challenges and practice gaps in precision medicine implementation, and the coordination of a multidisciplinary team to ensure optimal biomarker detection and targeted therapy utilization.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>